GlassScriptPhysician profile
Daniel J Hamilton
NPI 1366904260
$4,879.69
in general payments reported to CMS, 2019-2025
18 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $372 · 2023: $1,624 · 2024: $1,559 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,608 · Grant: $800 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,607.55 |
| Grant | $800.00 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,599.27 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $792.16 | 2022-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $667.48 | 2022-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $283.68 | 2024-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $249.98 | 2023-2024 | Glassia |
| Pfizer INC. | $224.99 | 2023 | |
| Optinose US, INC. | $160.90 | 2024-2025 | |
| Amgen INC. | $124.89 | 2024 | Actimmune |
| Ars Pharmaceuticals Operations, INC. | $124.89 | 2025 | Neffy |
| Pharming Healthcare, INC. | $120.65 | 2023 | Ruconest |
| Genentech USA, INC. | $119.36 | 2024 | Xolair |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Horizon Therapeutics Plc | $95.53 | 2022 | |
| Novartis Pharmaceuticals Corporation | $74.58 | 2024-2025 | |
| Biocryst US Sales Co., LLC | $68.34 | 2024 | Orladeyo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $29.26 | 2023 | Hizentra |
| Hikma Pharmaceuticals USA | $22.46 | 2025 | Ryaltris |
| Greer Laboratories, INC. | $21.32 | 2025 | Oralair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.